{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:04:06Z","timestamp":1789452246814,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"DOI":"10.1007\/s12149-026-02284-z","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:25:21Z","timestamp":1789449921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radium-223 therapy in metastatic castration-resistant prostate cancer: baseline predictors of treatment completion and survival in a reimbursement-regulated Taiwanese cohort"],"prefix":"10.1007","author":[{"given":"Hsi-Chen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ren","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Te","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Jie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Jung","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-4590","authenticated-orcid":false,"given":"Kung-Chu","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"3","key":"2284_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"2284_CR2","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1007\/s10147-025-02846-7","volume":"30","author":"N Masumori","year":"2025","unstructured":"Masumori N, Hosono M, Takahashi S, Kakehi Y, Uemura H, Sunaya T, et al. Post-marketing surveillance of radium-223 chloride in Japanese patients with castration-resistant prostate cancer with bone metastasis-final analysis of 3-year extended follow-up focusing on bone fractures. Int J Clin Oncol. 2025;30(10):2118\u201327.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2284_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/JCMA.0000000000001111","volume":"87","author":"SF Yao","year":"2024","unstructured":"Yao SF, Huang WJ, Wei TC, Wang YF, Lin KH, Hu LH, et al. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan. J Chin Med Assoc. 2024;87(7):734\u201340.","journal-title":"J Chin Med Assoc"},{"issue":"2","key":"2284_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.urolonc.2021.11.005","volume":"40","author":"D Sasaki","year":"2022","unstructured":"Sasaki D, Hatakeyama S, Kawaguchi H, Hatayama Y, Ishibashi Y, Kusaka A, et al. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study. Urol Oncol. 2022;40(2):64. e1- e8.","journal-title":"Urol Oncol"},{"issue":"9","key":"2284_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/iju.15008","volume":"29","author":"T Kawahara","year":"2022","unstructured":"Kawahara T, Miyoshi Y, Ninomiya S, Sato M, Takeshima T, Hasumi H, et al. Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study. Int J Urol. 2022;29(9):1079\u201384.","journal-title":"Int J Urol"},{"issue":"1","key":"2284_CR6","first-page":"13","volume":"11","author":"K Takeda","year":"2023","unstructured":"Takeda K, Kawasaki Y, Sakayauchi T, Takahashi C, Katagiri Y, Tanabe T, et al. Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer. Asia Ocean J Nucl Med Biol. 2023;11(1):13\u201322.","journal-title":"Asia Ocean J Nucl Med Biol"},{"issue":"9","key":"2284_CR7","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s00345-021-03639-z","volume":"39","author":"Y Miyoshi","year":"2021","unstructured":"Miyoshi Y, Tsutsumi S, Yasui M, Kawahara T, Uemura KI, Hayashi N, et al. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer. World J Urol. 2021;39(9):3323\u20138.","journal-title":"World J Urol"},{"issue":"1","key":"2284_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195\u2013202.","journal-title":"Cancer"},{"issue":"4","key":"2284_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.21873\/anticanres.16334","volume":"43","author":"HC Yang","year":"2023","unstructured":"Yang HC, Chang LW, Li JR, Wang SS, Yang CK, Chen CS, et al. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. Anticancer Res. 2023;43(4):1809\u201316.","journal-title":"Anticancer Res"},{"issue":"5","key":"2284_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.clgc.2019.05.012","volume":"17","author":"F Saad","year":"2019","unstructured":"Saad F, Gillessen S, Heinrich D, Keizman D, O\u2019Sullivan JM, Nilsson S, et al. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clin Genitourin Cancer. 2019;17(5):348\u201355. e5.","journal-title":"Clin Genitourin Cancer"},{"key":"2284_CR11","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.2147\/CMAR.S213051","volume":"11","author":"S Cheng","year":"2019","unstructured":"Cheng S, Arciero V, Goldberg H, Tajzler C, Manganaro A, Kozlowski N, et al. Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome. Cancer Manag Res. 2019;11:9307\u201319.","journal-title":"Cancer Manag Res"},{"issue":"7","key":"2284_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/ijc.35040","volume":"155","author":"CY Huang","year":"2024","unstructured":"Huang CY, Huang CP, Huang YY, Huang SK, Lu K, Huang WJ, et al. Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study. Int J Cancer. 2024;155(7):1268\u201377.","journal-title":"Int J Cancer"},{"issue":"4","key":"2284_CR13","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1002\/cam4.5262","volume":"12","author":"A Hyvakka","year":"2023","unstructured":"Hyvakka A, Kaariainen OS, Utriainen T, Loyttyniemi E, Mattila K, Reinikainen P, et al. Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study. Cancer Med. 2023;12(4):4064\u201376.","journal-title":"Cancer Med"},{"issue":"4","key":"2284_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.euo.2025.06.002","volume":"8","author":"M Lunan-Taylor","year":"2025","unstructured":"Lunan-Taylor M, Raval AD, Nhan Phan NT, Korn MJ, Quintero V, McKay RR. Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies. Eur Urol Oncol. 2025;8(4):1150\u201364.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"2284_CR15","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00259-022-06082-3","volume":"50","author":"K Kitajima","year":"2023","unstructured":"Kitajima K, Igeta M, Kuyama J, Kawahara T, Suga T, Otani T, et al. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial. Eur J Nucl Med Mol Imaging. 2023;50(5):1487\u201398.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2284_CR16","doi-asserted-by":"crossref","unstructured":"Kitajima K, Kuyama J, Kawahara T, Suga T, Otani T, Sugawara S et al. Assessing Therapeutic Response to Radium-223 with an Automated Bone Scan Index among Metastatic Castration-Resistant Prostate Cancer Patients: Data from Patients in the J-RAP-BSI Trial. Cancers (Basel). 2023;15(10).","DOI":"10.3390\/cancers15102784"},{"issue":"5","key":"2284_CR17","doi-asserted-by":"publisher","first-page":"e32671","DOI":"10.1097\/MD.0000000000032671","volume":"102","author":"PC Chiang","year":"2023","unstructured":"Chiang PC, Chiang PH, Chen IA, Chen YT, Wang HJ, Cheng YT, et al. Treatment outcomes with radium-223 in docetaxel-naive versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan. Med (Baltim). 2023;102(5):e32671.","journal-title":"Med (Baltim)"},{"issue":"12","key":"2284_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"10459","key":"2284_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339.","journal-title":"Lancet"},{"issue":"9","key":"2284_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","volume":"36","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F, Gallardo E, Soares A, Loriot Y, et al. Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. 2025;36(9):1058\u201367.","journal-title":"Ann Oncol"},{"issue":"4","key":"2284_CR21","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/jnumed.122.264456","volume":"64","author":"K Rahbar","year":"2023","unstructured":"Rahbar K, Essler M, Pabst KM, Eiber M, Fougere C, Prasad V, et al. Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study. J Nucl Med. 2023;64(4):574\u20138.","journal-title":"J Nucl Med"},{"issue":"1","key":"2284_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/bco2.42","volume":"2","author":"Y Miyoshi","year":"2021","unstructured":"Miyoshi Y, Yasui M, Ttsutsumi S, Kawahara T, Uemura KI, Hayashi N, et al. Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients. BJUI Compass. 2021;2(1):31\u20138.","journal-title":"BJUI Compass"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02284-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02284-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:25:23Z","timestamp":1789449923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-026-02284-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":22,"alternative-id":["2284"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02284-z","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"19 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no financial or non-financial conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}